Govinda Lohani, MD
Internal Medicine · N Little Rock, ARNPI 1063491355
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,566 and has fallen 88.9% since, to $174 in 2025. Among internal medicine clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $32.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$943
- AstraZeneca$881
- Johnson & Johnson$660
- Abbott$387
- Amarin Pharma, Inc.$265
- Bayer$208
- plus $1K from 19 others
Across 13 payments — averaging $3855.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$28K
- AstraZeneca$22K
What the payments were for
- Food & beverage$4,376100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 39 | $943 |
| AstraZeneca | 21 | $881 |
| Johnson & Johnson | 18 | $660 |
| Abbott | 14 | $387 |
| Amarin Pharma, Inc. | 5 | $265 |
| Bayer | 8 | $208 |
| Pfizer | 4 | $158 |
| Idorsia Pharmaceuticals US Inc | 2 | $127 |
| Gilead | 1 | $125 |
| Novo Nordisk | 2 | $116 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $110 |
| Sanofi | 1 | $90 |
| AbbVie | 2 | $75 |
| Boehringer Ingelheim | 3 | $52 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Lilly USA, LLC | 2 | $26 |
| Merck | 1 | $19 |
| Novartis | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Vifor Pharma, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$459
- XARELTO$236
- Vascepa$233
- FreeStyle Libre Pro$158
- Biktarvy$125
- PAXLOVID$114
- QUVIVIQ$113
- TRELEGY ELLIPTA$105
How this compares
$4,387 in reported general payments places this provider in the 90th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 184 | $165,809 |
| JardianceEmpagliflozin | 81 | $75,794 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 107 | $71,085 |
| EliquisApixaban | 49 | $48,685 |
| OzempicSemaglutide | 34 | $40,960 |
| XareltoRivaroxaban | 26 | $27,375 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 40 | $21,731 |
| JanuviaSitagliptin Phosphate | 29 | $21,656 |
| TrulicityDulaglutide | 11 | $11,038 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $10,003 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 61 | $9,634 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $8,913 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $7,561 |
| Gabapentin | 285 | $5,993 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $5,408 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $881 | $165,809184 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $943 | $101,728166 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $52 | $85,797101 claims |
| PfizerEliquis | $158 | $48,68549 claims |
| Novo NordiskOzempic | $116 | $40,96034 claims |
| Johnson & JohnsonXarelto | $660 | $27,37526 claims |
| MerckJanuvia | $19 | $21,65629 claims |
| Lilly USA, LLCTrulicity | $26 | $11,03811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in N Little Rock
- David PyleJonesboro$93K
- Aaron StrobelLittle Rock$32K
- Stuart BensonRogers$24K
- Purnima SarkarEarle$21K
- John NorwoodJonesboro$21K
- Ahmed AliConway$18K
- Jeremy DavisLittle Rock$17K
- Tyree SealsFort Smith$14K
- Atif KhanBatesville$14K
- Ritesh RampureLittle Rock$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.